Literature DB >> 1835856

Changing clinical presentation of multiple myeloma.

A Riccardi1, P G Gobbi, G Ucci, D Bertoloni, R Luoni, L Rutigliano, E Ascari.   

Abstract

We compared the presentation features of three series of patients with multiple myeloma diagnosed between 1960 and 1971 (Kyle R, Mayo Clin Proc, 1975, 50, 29, n = 869), 1972 and 1986 (Clinica Medica, University of Pavia, n = 345) and 1987 and 1990 (Cooperative Group for Study and Treatment of Multiple Myeloma, n = 341). In the most recently diagnosed patients, the percentage of those who had symptoms related to multiple myeloma (i.e. any of bone pain, systemic symptoms, disturbances related to hypercalcemia, neurological involvement and hyperviscosity) was reduced (90 vs. 86 vs. 66%) (P less than 0.001), while the percentage of asymptomatic patients diagnosed by chance was increased (not reported, and 14 vs. 34%). In the most recent series, a lower percentage of spontaneous bone pain (68 vs. 60 vs. 37%, P less than 0.001) paralleled a lower incidence of advanced bone disease (osteolyses and pathological fractures, 60 vs. 64 vs. 34%), and renal failure (serum creatinine greater than 1.2 mg/dl) was also less common (56 vs. 44 vs. 33%, P less than 0.01), at least partially due to a decreased incidence of both hypercalcemia (30 vs. 20 vs. 18%, P less than 0.001) and of hyperuricemia (serum uric acid greater than 7 mg/dl, 47 vs. 32 vs. 26%, P less than 0.01). Systemic symptoms (weakness, infections, fever or weight loss) were reported more seldom by recently diagnosed patients, due to a decreased frequency of anaemia (haemoglobin less than 12 g/dl), leukopenia and thrombocytopenia, as well as of the systemic effects of bone pain and of renal insufficiency. These data indicate that multiple myeloma is diagnosed earlier now than in the past, and this must be taken into account when comparing survival data in treated series.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1835856     DOI: 10.1016/0277-5379(91)90020-e

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  18 in total

Review 1.  [What should be done in weight loss of unknown origin?].

Authors:  A Schwenk
Journal:  Med Klin (Munich)       Date:  1998-12-15

2.  Three cases of synchronous solid tumor and multiple myeloma.

Authors:  Sang Hoon Ji; Joon Oh Park; Jeeyun Lee; Mi Jung Oh; Do Hyoung Lim; Byeong-Bae Park; Keun Woo Park; Se-Hoon Lee; Kihyun Kim; Won Seog Kim; Chul Won Jung; Young Suk Park; Young-Hyuck Im; Won Ki Kang; Mark H Lee; Keunchil Park
Journal:  Cancer Res Treat       Date:  2004-10-31       Impact factor: 4.679

Review 3.  Rheumatological manifestations of haematological diseases.

Authors:  S Menon; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

4.  Unilateral massive pleural effusion: a presentation of unsuspected multiple myeloma.

Authors:  Alok G Ghoshal; Supriya Sarkar; Anup Majumder; Sudipta Chakrabarti
Journal:  Indian J Hematol Blood Transfus       Date:  2010-10-07       Impact factor: 0.900

5.  Clinical significance of cancer-related fatigue in multiple myeloma patients.

Authors:  Kazuhito Suzuki; Nobuyuki Kobayashi; Yoji Ogasawara; Takaki Shimada; Yuichi Yahagi; Katsuki Sugiyama; Shinobu Takahara; Takeshi Saito; Jiro Minami; Hiroki Yokoyama; Yutaro Kamiyama; Atsushi Katsube; Kazuhiro Kondo; Hiroyuki Yanagisawa; Keisuke Aiba; Shingo Yano
Journal:  Int J Hematol       Date:  2018-08-28       Impact factor: 2.490

Review 6.  Kidney injury and disease in patients with haematological malignancies.

Authors:  Frank Bridoux; Paul Cockwell; Ilya Glezerman; Victoria Gutgarts; Jonathan J Hogan; Kenar D Jhaveri; Florent Joly; Samih H Nasr; Deirdre Sawinski; Nelson Leung
Journal:  Nat Rev Nephrol       Date:  2021-03-30       Impact factor: 28.314

7.  A prognostic index for multiple myeloma.

Authors:  G Grignani; P G Gobbi; R Formisano; C Pieresca; G Ucci; S Brugnatelli; A Riccardi; E Ascari
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

8.  Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; O Mora; C Tinelli; D Valentini; S Brugnatelli; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; M Giordano; C Delfini; G Nicoletti; C Bergonzi; E Rinaldi; L Piccinini; E Ascari
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

9.  Plasma cell myeloma initially presenting as lung cancer.

Authors:  Sun Young Cho; Jae-Heon Jeong; Woo-In Lee; Juhie Lee; Il Ki Hong; Jin-Tae Suh; Hee Joo Lee; Hwi-Joong Yoon; Tae Sung Park
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464

10.  Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; G Ucci; R Luoni; S Brugnatelli; O Mora; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; F Alberio
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.